Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.23374/fullpdf
Reference39 articles.
1. CA 125: The past and the Future
2. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
3. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
4. Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Gynecologic Cancer InterGroup CA125 response has a high negative predictive value for CHK1 inhibitor RECIST response in recurrent ovarian cancer;Scientific Reports;2024-07-29
2. Targeted therapy and molecular genetics;DiSaia and Creasman Clinical Gynecologic Oncology;2023
3. Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer;Scientific Reports;2021-09-14
4. Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer;Journal of Ovarian Research;2021-01-11
5. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study);Gynecologic Oncology;2020-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3